Asenapine maleate | Org 5222 maleate;Org 5222 | 阿塞那平盐酸盐 | 5-HT Receptor

首页 / 抑制剂/激动剂 / / 5-羟色胺受体 / Asenapine maleate/阿塞那平马来酸盐

Asenapine maleate/阿塞那平马来酸盐 {[allProObj[0].p_purity_real_show]}

货号：A504366 同义名： 阿塞那平盐酸盐 / Org 5222 maleate; Org 5222

Asenapine maleate 是一种高亲和性 5-HT 和 D2 受体拮抗剂（Ki 分别为 0.03–4.0 nM 和 1.3 nM），并具有多种 5-HT 受体亚型拮抗作用，适用于精神分裂症和双相情感障碍等精神疾病模型的研究。

Asenapine maleate/阿塞那平马来酸盐化学结构
CAS号：85650-56-2

Asenapine maleate/阿塞那平马来酸盐 3D分子结构
CAS号：85650-56-2

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Asenapine maleate/阿塞那平马来酸盐纯度/质量文件产品仅供科研

货号：A504366 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]; • Cell, 2025. Ambeed. [ A122167 ]; • Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]; • Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]; • Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]; 更多 >

5-羟色胺受体亚型比较

产品名称	5-HT ↓ ↑	5-HT1 ↓ ↑	5-HT2 ↓ ↑	5-HT3 ↓ ↑	5-HT5 ↓ ↑	5-HT6 ↓ ↑	5-HT7 ↓ ↑	其他靶点	纯度
Desvenlafaxine	++ 5-HT, Ki: 40.2 nM								98%
Lamotrigine	+ 5-HT (rat brain synaptosomes), IC50: 474 μM 5-HT (human platelets), IC50: 240 μM								98%
Venlafaxine	✔								99%
Fluvoxamine maleate	✔								99%
Iloperidone	✔								99%
Ziprasidone HCl	✔								98+%
Atomoxetine HCI	+ 5-HT, Ki: 77 nM								98%
Dapoxetine HCl	✔								97%
Trazodone	✔								98+%
Clomipramine HCl	✔								98%
Mirtazapine	✔								99+%
Escitalopram oxalate	+++ 5-HT, Ki: 0.89 nM								97%
Duloxetine	✔								97%
Sertraline HCl	++ 5-HT, Ki: 13 nM								98%
Citalopram HBr	+++ serotonin reuptake, IC50: 1.8 nM								98%
Latrepirdine 2HCl	✔							GluR	99%
Fluoxetine HCl	✔								99.5%
Paroxetine HCl	✔							AChR	99%
BMY 7378		++ 5-HT1D, pIC50: 5.9 5-HT1A, pIC50: 6.4	+ 5-HT2, pIC50: 5.5						97%
Flibanserin		+++ 5-HT1A, Ki: 1 nM	+ 5-HT2A, Ki: 49 nM						95%
LY310762		+ 5-HT1D, Ki: 249 nM							99%+
Cyclobenzaprine HCI			✔						99%
Blonanserin			+++ 5-HT2, Ki: 3.98 nM						99%
Cyproheptadine HCl			++++ 5-HT2, IC50: 0.6 nM						99+%
Olanzapine			✔						99+%
Pimavanserin hemitartrate			+++ 5-HT2A, pIC50: 8.7						99%
Ketanserin			+++ 5-HT2C (Rat), Ki: 50 nM 5-HT2C (Human), Ki: 2.5 nM						99%+
Loxapine succinate			++ 5-HT2 (human), Ki: 6.8 nM 5-HT2 (bovine), Ki: 6.6 nM						98%
Agomelatine			✔						98%
Clozapine			✔						98%
Amitriptyline			+ 5-HT2, Ki: 235 nM					SERT	99%
PRX-08066 maleate			+++ 5-HT2B, IC50: 3.4 nM						98+%
RS-127445			++++ 5-HT2B, pIC50: 10.4 5-HT2B, pKi: 9.5						99%+
Sarpogrelate HCl			++++ 5-HT2A, Kd: 2.1 nM 5-HT2C, Kd: 1.1 nM						98%
Tropisetron				✔					99%
Ramosetron HCl				++++ 5-HT3 receptor, Ki: 0.091 nM					98%
Ondansetron				✔					99%
Granisetron				✔					98%
Alosetron HCl				✔					98%
Ondansetron HCl dihydrate				✔					98%
VUF10166				++++ 5-HT3AB, Ki: 22 nM 5-HT3A, Ki: 0.04 nM					99%+
Azasetron HCl				++++ 5-HT3, IC50: 0.33 nM					99%
Asenapine maleate		+++ 5-HT1B, pKi: 8.4 5-HT1A, pKi: 8.6	++++ 5-HT2C, pKi: 10.46 5-HT2A, pKi: 9.75		+++ 5-HT5A, pKi: 8.84	++++ 5-HT6, pKi: 9.6	++++ 5-HT7, pKi: 9.94		97%
Risperidone		++ 5-HT1B, Ki: 14.9 nM 5-HT1D, Ki: 84.6 nM	++++ 5-HT2A, Ki: 61.9 nM 5-HT2C, Ki: 12 nM		+ 5-HT5A, Ki: 206 nM		++ 5-HT7, Ki: 6.6 nM		98%
SB 271046 HCl						+++ 5-HT6, pKi: 8.92			99%+
Intepirdine						++++ 5-HT6, pKi: 9.63			99%+
SB-269970 HCl							++ 5-HT7, pKi: 8.3		98+%
BRL 15572		++ 5-HT1D, pKi: 6 5-HT1B, pKi: 6.1	++ 5-HT2A, pKi: 6.6 5-HT2B, pKi: 6.2			+ 5-HT6, pKi: 5.9	+ 5-HT7, pKi: 6.3		95%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Asenapine maleate/阿塞那平马来酸盐生物活性

靶点

α-adrenergic receptor

α2B-adrenergic receptor, pKi:8.9

α2A-adrenergic receptor, pKi:8.9
5-HT2

5-HT2C, pKi:10.46

5-HT2A, pKi:9.75
5-HT6

5-HT6, pKi:9.6
5-HT1

5-HT1B, pKi:8.4

5-HT1A, pKi:8.6

描述

Asenapine maleate is an antagonist of 5-HT (1a, 1b, 2a, 2b, 2C, 5A, 6, 7) and D2, with Ki values of 0.03-4.0 nm and 1.3 nm, respectively and also an antipsychotic^[3]. Asenapine reduced freezing behaviour and increased serotonin release in the rat hippocampus^[4]. Asenapine ameliorated this serotonin deficit in a dose-related manner that matched its efficacy for reversing the cognitive deficit^[5].In vivo, Asenapine displays robust antimanic property and effective antagonistic activity at 5‐HT 1A/7 receptors^[6].

Asenapine maleate/阿塞那平马来酸盐临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02181803	Schizophrenia	Phase 1	Completed	-	-
NCT02600741	-		Completed	-	-
NCT03565068	Schizophrenia	Phase 1	Suspended(Study is on hold pen... 展开 >>ding evaluation of emerging preclinical findings) 收起 <<	October 9, 2019	United States, California ... 展开 >> California Clinical Trials ( Site 0001) Glendale, California, United States, 91206 收起 <<

Asenapine maleate/阿塞那平马来酸盐参考文献

[1]Stoner SC, Pace HA. Asenapine: a clinical review of a second-generation antipsychotic. Clin Ther. 2012 May;34(5):1023-40.

[2]Shahid M, Walker GB, et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73.

[3]Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. PMID: 18308814.

[4]Ohyama M, Kondo M, Yamauchi M, Imanishi T, Koyama T. Asenapine reduces anxiety-related behaviours in rat conditioned fear stress model. Acta Neuropsychiatr. 2016 Dec;28(6):327-336. doi: 10.1017/neu.2016.17. Epub 2016 Apr 21. PMID: 27099073.

[5]Elsworth JD, Groman SM, Jentsch JD, Valles R, Shahid M, Wong E, Marston H, Roth RH. Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration. Neuropharmacology. 2012 Mar;62(3):1442-52. doi: 10.1016/j.neuropharm.2011.08.026. Epub 2011 Aug 23. PMID: 21875607; PMCID: PMC3711239.

[6]Delcourte S, Abrial E, Etiévant A, Rovera R, Arnt J, Didriksen M, Haddjeri N. Asenapine modulates mood-related behaviors and 5-HT1A/7 receptors-mediated neurotransmission. CNS Neurosci Ther. 2017 Jun;23(6):518-525. doi: 10.1111/cns.12698. Epub 2017 Apr 17. PMID: 28417559; PMCID: PMC6492759.

Asenapine maleate/阿塞那平马来酸盐实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.49mL

0.50mL

0.25mL

12.44mL

2.49mL

1.24mL

24.89mL

4.98mL

2.49mL

Asenapine maleate/阿塞那平马来酸盐技术信息

CAS号	85650-56-2
分子式	C₂₁H₂₀ClNO₅
分子量	401.84
SMILES Code	CN1C[C@]2([H])C3=CC=CC=C3OC4=CC=C(Cl)C=C4[C@]2(C1)[H].O=C(O)/C=C\C(O)=O
MDL No.	MFCD00900588

别名	阿塞那平盐酸盐 ;Org 5222 maleate; Org 5222
运输	蓝冰

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Inert atmosphere, 2-8°C

溶解方案

细胞实验：

DMSO: 25 mg/mL(62.21 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H₂O: 6 mg/mL(14.93 mM)

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

方案三

配制的工作液建议现用现配，短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02181803	Schizophrenia	Phase 1	Completed	-	-
NCT02600741	-		Completed	-	-
NCT03565068	Schizophrenia	Phase 1	Suspended(Study is on hold pen... 展开 >>ding evaluation of emerging preclinical findings) 收起 <<	October 9, 2019	United States, California ... 展开 >> California Clinical Trials ( Site 0001) Glendale, California, United States, 91206 收起 <<
NCT02893371	-		Enrolling by invitation	June 2019	United States, New Mexico ... 展开 >> Christophe G Lambert Albuquerque, New Mexico, United States, 87131 收起 <<
NCT02213887	Psychotic Disorders ... 展开 >> Gastroesophageal Reflux 收起 <<	Phase 4	Active, not recruiting	August 2018	Canada, British Columbia ... 展开 >> UBC Hospital - Detwiller Pavilion Vancouver, British Columbia, Canada, V6T 2A1 收起 <<
NCT01498770	-		Completed	-	-
NCT00806234	Psychotic Disorders	Phase 4	Completed	-	United States, Maryland ... 展开 >> University of Maryland Baltimore, Maryland, United States, 21201 Johns Hopkins Hospital Baltimore, Maryland, United States, 21205 United States, New York The Zucker Hillside Hospital Glen Oaks, New York, United States, 11004 United States, North Carolina University of North Carolina, Division of Child and Adolescent Psychiatry Chapel Hill, North Carolina, United States, 27599 收起 <<
NCT00265343	Schizophrenia	Phase 3	Completed	-	-
NCT00806234	-		Completed	-	-
NCT00156104	Schizophrenia	Phase 3	Completed	-	-
NCT00156117	Schizophrenia	Phase 3	Completed	-	-
NCT00265343	-		Completed	-	-
NCT00145496	Schizophrenia	Phase 3	Completed	-	-
NCT01765829	Psychosis Nos/Other	Phase 3	Unknown	November 2015	Spain ... 展开 >> Mental Health Unit Villamartín Recruiting Villamartín, Cádiz, Spain, 11650 Contact: José María Mongil San Juan, MD 0034956040209 cheman45@gmail.com Principal Investigator: José María Mongil San Juan, MD Mental Health Unit Baza Recruiting Baza, Granada, Spain, 18800 Contact: Eva Bravo Barba, MD eva.bravo.barba@gmail.com Principal Investigator: Eva Bravo Barba, MD Mental Health Unit Motril Recruiting Motril, Granada, Spain, 18600 Contact: María Luisa Barrigón Estévez, MD 0034958038849 marial.barrigon.sspa@juntadeandalucia.es Principal Investigator: María Luisa Barrigón Estévez, MD Mental Health Unit Andújar Recruiting Andújar, Jaén, Spain, 23740 Contact: Fernando Sarramea Crespo, MD, PhD 0034953021717 fernandosarramea@hotmail.com Principal Investigator: Farnando Sarramea Crespo, MD, PhD Mental Health Unit Martos Recruiting Martos, Jaén, Spain, 23600 Contact: Miguel Ortigosa Luque, MD migueortigosa@hotmail.com Principal Investigator: Miguel Ortigosa Luque, MD Mental Health Unit Miraflores Not yet recruiting Alcobendas, Madrid, Spain, 28100 Contact: María Luisa Zamarro Arraz, MD, PhD 0034916530108 zamarroluisa@yahoo.es Principal Investigator: María Luisa Zamarro Arraz, MD, PhD Hospital Infanta Sofía Not yet recruiting San Sebastian de los Reyes, Madrid, Spain, 28702 Contact: María Rosario Gutiérrez Labrador, MD rosagutierrez@psiquiatra.e.telefonica.net Principal Investigator: María Rosario Guitiérrez Labrador, MD Mental Health Unit Valle del Guadalhorce Not yet recruiting Cártama, Málaga, Spain, 29580 Contact: Daniel Gutiérrez Castillo, MD 0034951033931 dgutierrezcastillo@gmail.com Principal Investigator: Daniel Gutiérrez Castillo, MD Mental Health Unit Las Lagunas Not yet recruiting Fuengiróla, Málaga, Spain, 29650 Contact: María Isabel Osuna Carmona, MD maribelosunac@hotmail.com Principal Investigator: María Isabel Osuna Carmona, MD Fundación Argibide Not yet recruiting Pamplona, Navarra, Spain, 31007 Contact: Ignacio Mata Pastor, MD, PhD 0034948266650 nacho.mata70@gmail.com Principal Investigator: Ignacio Mata Pastor, MD, PhD Hospital El Tomillar Recruiting Dos Hermanas, Seville, Spain, 41700 Contact: Joaquín Carlos Martín Muñoz, MD, PhD 0034955016083 joaquinmartin@hotmail.com Principal Investigator: Joaquín Carlos Martín Muñoz, MD, PhD Hospital Francesc de Borja Recruiting Gandía, Valencia, Spain, 46700 Contact: María Lacruz Silvestre, MD, PhD maria.lacruz.silvestre@gmail.com Principal Investigator: María Lacruz Silvestre, MD, PhD Hospital de Basurto Not yet recruiting Bilbao, Spain, 48013 Contact: Sonia Bustamante Madariaga, MD, Phd 0034944 006137 sonia.bustamantemadariaga@osakidetza.net Principal Investigator: Sonia Bustamante Madariaga, MD, PhD Mental Health Unit Tetuán Not yet recruiting Madrid, Spain, 28003 Contact: Mariano Hernández Monsalve, MD, PhD 0034915347363 hergoico@gmail.com Contact: Ruth Berdún Pe, MD ruthberdun@yahoo.es Principal Investigator: Mariano Hernández Monsalve, MD, PhD Lafora Hospital Not yet recruiting Madrid, Spain, 28049 Contact: Juan Dios Molina Martín, MD, PhD jmolinamar@hotmail.com Principal Investigator: Juan Dios Molina Martín, MD, PhD Hospital Carlos Haya Recruiting Málaga, Spain, 29009 Contact: Fermín Mayoral Cleríes, Md, PhD fermin.mayoral.sspa@juntadeandalucia.es Principal Investigator: Fermín Mayoral Cleríes, MD, PhD Virgen del Rocío Hospital Recruiting Seville, Spain, 41013 Contact: Clara M. Rosso Fernández, MD 0034955013414 claram.rosso.sspa@juntadeandalucia.es Contact: Miguel Ruiz Veguilla, MD, PhD 0034955013414 mruizveguilla@yahoo.com Principal Investigator: Miguel Ruiz Veguilla, MD, PhD 收起 <<
NCT00212836	Schizophrenia	Phase 3	Completed	-	-
NCT00174265	Schizophrenia	Phase 3	Completed	-	-
NCT00145496	-		Completed	-	-
NCT00151424	Schizophrenia	Phase 3	Completed	-	-
NCT00174265	-		Completed	-	-
NCT00156091	Schizophrenia	Phase 3	Completed	-	-
NCT01617187	Schizophrenia	Phase 3	Completed	-	-
NCT02072954	Schizophrenia	Phase 2 Phase 3	Completed	-	India ... 展开 >> Shri Hatkesh Healthcare Foundation Junagadh, Gujurat, India, 362 001 Divyam Hospital Surat, Gujurat, India, 395 001 收起 <<
NCT01617200	Schizophrenia	Phase 3	Completed	-	United States, Texas ... 展开 >> Forest Investigative Site 2001 Austin, Texas, United States, 78754 收起 <<
NCT02876900	Schizophrenia	Phase 3	Completed	-	United States, New York ... 展开 >> Noven Pharmaceuticals, Inc. New York, New York, United States, 10118 收起 <<
NCT01495741	-		Completed	-	-
NCT01617187	-		Completed	-	-
NCT00212771	Schizophrenia ... 展开 >> Schizoaffective Disorder 收起 <<	Phase 3	Completed	-	-
NCT00156065	Schizophrenia	Phase 3	Completed	-	-
NCT01765127	-		Completed	-	United Kingdom ... 展开 >> Drug Safety Research Unit (for data collation and analysis only) Southampton, Hampshire, United Kingdom, SO31 1AA 收起 <<
NCT00156065	-		Completed	-	-
NCT00212784	Schizophrenia ... 展开 >> Schizoaffective Disorder 收起 <<	Phase 3	Completed	-	-
NCT00878462	Psychosis	Phase 2	Completed	-	-
NCT01734278	-		Completed	-	United Kingdom ... 展开 >> South Staffordshire and Shropshire Healthcare NHS Foundation Trust Stafford, Staffordshire, United Kingdom, ST16 3SR 收起 <<
NCT01098110	Schizophrenia	Phase 3	Completed	-	-
NCT00159744	Bipolar Disorder	Phase 3	Completed	-	-
NCT01098110	-		Completed	-	-
NCT00159796	Bipolar Disorder	Phase 3	Completed	-	-
NCT01948024	Schizophrenia ... 展开 >> Bipolar Disorder 收起 <<	Phase 1	Completed	-	United States, Arkansas ... 展开 >> Woodland International Research Group, Inc. Little Rock, Arkansas, United States, 72211 United States, California Clinical Innovations, Inc Costa Mesa, California, United States, 92280 Collaborative Neuroscience Network, LLC Garden Grove, California, United States, 92845 United States, Florida Compass Research North, LLC Leesburg, Florida, United States, 34748 Advanced Pharma CR, LLC Miami, Florida, United States, 33136 United States, Georgia Atlanta Center for Medical Research Atlanta, Georgia, United States, 30308 United States, North Carolina New Hope Clinical Research Charlotte, North Carolina, United States, 28204 收起 <<
NCT00150176	-		Completed	-	-
NCT01244828	Schizophrenia	Phase 3	Completed	-	-
NCT01244828	-		Completed	-	-
NCT01142596	Schizophrenia	Phase 3	Completed	-	-
NCT01142596	-		Completed	-	-
NCT00159783	-		Completed	-	-
NCT00145470	Bipolar Disorder	Phase 3	Completed	-	-
NCT00150176	Schizophrenia	Phase 3	Completed	-	-
NCT01670019	-		Completed	-	-
NCT01670019	Major Depressive Disorder With... 展开 >>out Psychotic Features 收起 <<	Phase 4	Completed	-	United States, Georgia ... 展开 >> Georgia Health Sciences University Augusta, Georgia, United States, 30912 United States, North Carolina Carolina Behavioral Care Durham, North Carolina, United States, 27704 Duke University Medical Center Durham, North Carolina, United States, 27710 Brody School of Medicine at East Carolina University Greenville, North Carolina, United States, 27834 North Carolina Psychiatric Research Center Raleigh, North Carolina, United States, 27603 收起 <<
NCT00764478	-		Completed	-	-
NCT00764478	Bipolar 1 Disorder	Phase 3	Completed	-	-
NCT00145509	Bipolar Disorder	Phase 3	Completed	-	-
NCT00145509	-		Completed	-	-
NCT01244815	Bipolar Disorder, Pediatric	Phase 3	Completed	-	-
NCT01206517	-		Completed	-	-
NCT01206517	Schizophrenia ... 展开 >> Bipolar I Disorder 收起 <<	Phase 1	Completed	-	-
NCT01244815	-		Completed	-	-
NCT00159783	Bipolar Disorder	Phase 3	Completed	-	-
NCT00143182	Bipolar Disorder	Phase 3	Completed	-	-
NCT00281320	Psychosis	Phase 3	Completed	-	-
NCT00281320	-		Completed	-	-
NCT01400113	Agitation	Phase 4	Completed	-	United States, New York ... 展开 >> St. Joseph's Hospital Health Center-Comprehensive Psychiatric Emergency Program (CPEP) Syracuse, New York, United States, 13203 收起 <<
NCT01400113	-		Completed	-	-
NCT01190254	-		Completed	-	-
NCT01807741	Bipolar Depression	Phase 2	Terminated(funding ended due t... 展开 >>o recruitment delays) 收起 <<	-	United States, Ohio ... 展开 >> University of Cincinnati Cincinnati, Ohio, United States, 45244 收起 <<
NCT01396291	Bipolar 1 Disorder	Phase 3	Completed	-	-
NCT01190254	Schizophrenia, Paranoid ... 展开 >> Schizophrenia, Disorganized Schizophrenia, Undifferentiated 收起 <<	Phase 3	Completed	-	-
NCT01101464	Schizophrenia ... 展开 >> Schizoaffective Disorder 收起 <<	Phase 2	Completed	-	-
NCT01684657	Stuttering	Phase 3	Suspended(Study transferring t... 展开 >>o another facility) 收起 <<	May 2014	United States, California ... 展开 >> University of California Irvine Medical Center Orange, California, United States, 92868 收起 <<
NCT01101464	-		Completed	-	-
NCT01395992	Bipolar I Disorder	Phase 3	Completed	-	United States, Texas ... 展开 >> Forest Investigative Site 1000 Austin, Texas, United States, 78754 收起 <<
NCT01587118	Posttraumatic Stress Disorder	Phase 4	Completed	-	United States, Alabama ... 展开 >> Tuscaloosa VA Medical Center Tuscaloosa, Alabama, United States, 35404 收起 <<
NCT01190267	-		Completed	-	-
NCT01349907	-		Completed	-	-
NCT01549041	Schizophrenia	Phase 4	Completed	-	United States, North Carolina ... 展开 >> Central Regional Hospital Butner, North Carolina, United States, 27609 收起 <<
NCT01349907	Bipolar Disorder	Phase 3	Completed	-	-
NCT01549041	-		Completed	-	-
NCT01587118	-		Completed	-	-
NCT01460290	Bipolar Disorder	Phase 4	Completed	-	United States, Ohio ... 展开 >> University Hospitals Case Medical Center Cleveland, Ohio, United States, 44106 收起 <<
NCT01190267	Schizophrenia, Paranoid ... 展开 >> Schizophrenia, Disorganized Schizophrenia, Undifferentiated 收起 <<	Phase 3	Completed	-	-
NCT01460290	-		Completed	-	-
NCT01968161	Schizophrenia and Disorders Wi... 展开 >>th Psychotic Features Disorders 收起 <<	Phase 4	Unknown	March 2014	Canada ... 展开 >> Clinique Notre-Dame des Victoires Recruiting Quebec, Canada, G1K 4B2 Contact: Diana Pasat, BSc 418-694-2223 diana.pasat@yahoo.ca Principal Investigator: Marc-Andre Roy, MD 收起 <<

Asenapine maleate/阿塞那平马来酸盐 {[allProObj[0].p_purity_real_show]}

Asenapine maleate/阿塞那平马来酸盐纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Asenapine maleate/阿塞那平马来酸盐质控信息

Asenapine maleate/阿塞那平马来酸盐生物活性

Asenapine maleate/阿塞那平马来酸盐临床研究

Asenapine maleate/阿塞那平马来酸盐参考文献

Asenapine maleate/阿塞那平马来酸盐实验方案

Asenapine maleate/阿塞那平马来酸盐技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

α-adrenergic receptor	α2B-adrenergic receptor, pKi:8.9 α2A-adrenergic receptor, pKi:8.9
5-HT2	5-HT2C, pKi:10.46 5-HT2A, pKi:9.75
5-HT6	5-HT6, pKi:9.6
5-HT1	5-HT1B, pKi:8.4 5-HT1A, pKi:8.6
5-HT5	5-HT5A, pKi:8.84
5-HT7	5-HT7, pKi:9.94

Asenapine maleate/阿塞那平马来酸盐 {[allProObj[0].p_purity_real_show]}

Asenapine maleate/阿塞那平马来酸盐 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Asenapine maleate/阿塞那平马来酸盐 质控信息

Asenapine maleate/阿塞那平马来酸盐 生物活性

Asenapine maleate/阿塞那平马来酸盐 临床研究

Asenapine maleate/阿塞那平马来酸盐 参考文献

Asenapine maleate/阿塞那平马来酸盐 实验方案

Asenapine maleate/阿塞那平马来酸盐 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Asenapine maleate/阿塞那平马来酸盐纯度/质量文件产品仅供科研

Asenapine maleate/阿塞那平马来酸盐质控信息

Asenapine maleate/阿塞那平马来酸盐生物活性

Asenapine maleate/阿塞那平马来酸盐临床研究

Asenapine maleate/阿塞那平马来酸盐参考文献

Asenapine maleate/阿塞那平马来酸盐实验方案

Asenapine maleate/阿塞那平马来酸盐技术信息